Retatrutide Research for Obesity
An evidence-based overview of research examining Retatrutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Retatrutide has demonstrated the most substantial weight loss of any incretin-based therapy in clinical trials. Phase 2 data showed up to 24.2% weight loss at 48 weeks (12mg dose), with 93% of participants achieving at least 10% weight loss and 83% achieving at least 15%. The first Phase 3 results (TRIUMPH-4) showed 28.7% weight loss at 68 weeks.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Retatrutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.